Pfizer, Teva reach deal to allow generic Viagra

by The Associated Press

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

Pfizer says Teva will pay an undisclosed royalty for a license to produce a of Viagra, one of New York-based Pfizer's best-selling drugs. Viagra generated about $1.14 billion in U.S. sales last year.

Pfizer's patent protecting Viagra from generic competition expires in April 2020, but Teva will be allowed to launch its generic version Dec. 11, 2017.

Pfizer Inc. had sued Teva in 2010 over the Israeli drugmaker's plans to introduce a generic version of Viagra.

The patent protecting another , Eli Lilly and Co.'s Cialis, also expires in 2017.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Canada high court voids Pfizer's Viagra patent

Nov 08, 2012

Canada's top court on Thursday stripped Pfizer of its patent for Viagra, saying the pharmaceutical giant failed in the patent to identify the active compound in the drug.

Slovenia to launch generic version of Viagra

Jul 31, 2009

Krka, the biggest drugmaker in Slovenia, said Friday that its generic version of the impotency drug Viagra would be launched in September and priced 30 percent cheaper than the original.

FDA approves first generic versions of Cymbalta

Dec 11, 2013

The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, ...

S. Korea to approve Viagra generics

Mar 14, 2012

Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday.

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments